Portola Pharmaceuticals, Inc. (PTLA)
Stock Price Chart
Key Info
| Market Cap | 1.40B |
| Revenue (ttm) | 120.86M |
| Net Income (ttm) | -281.28M |
| Shares Out | 78.48M |
| EPS (ttm) | -3.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 2, 2020 |
| Last Price | $18.03 |
| Previous Close | $18.03 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 17.99 - 18.07 |
| Day's Volume | 0 |
| 52-Week Range | 5.31 - 31.73 |
More Stats
| Market Cap | 1.40B |
| Enterprise Value | 1.39B |
| Earnings Date (est) | Aug 11, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 78.48M |
| Float | 77.64M |
| EPS (basic) | -3.80 |
| EPS (diluted) | -3.78 |
| FCF / Share | -3.17 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 12.95M |
| Short Ratio | 4.50 |
| Short % of Float | 16.68% |
| Beta | 2.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 11.61 |
| PB Ratio | 19.64 |
| Revenue | 120.86M |
| Operating Income | -256.12M |
| Net Income | -281.28M |
| Free Cash Flow | -247.57M |
| Net Cash | 14.77M |
| Net Cash / Share | 0.19 |
| Gross Margin | -18.01% |
| Operating Margin | -211.92% |
| Profit Margin | -232.70% |
| FCF Margin | -204.84% |
| ROA | -30.59% |
| ROE | -462.25% |
| ROIC | -48.60% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 40.13 | 22.55 | 35.50 | 12.07 | 9.63 | 10.53 | 72.04 | 78.03 | 35.27 |
| Revenue Growth | 190.66% | 77.99% | -36.5% | 194.15% | 25.4% | -8.6% | -85.38% | -7.67% | 121.25% | - |
| Gross Profit | 72.26 | 22.05 | 22.13 | 35.50 | 12.07 | 9.63 | 10.53 | 72.04 | 78.03 | 35.27 |
| Operating Income | -271 | -345 | -273 | -270 | -227 | -138 | -84.18 | 10.86 | 19.87 | -18.75 |
| Net Income | -291 | -350 | -286 | -269 | -227 | -137 | -83.35 | - | 0.08 | -20.27 |
| Shares Outstanding | 71.56 | 66.02 | 59.51 | 56.48 | 51.98 | 42.98 | 22.84 | 1.35 | 1.25 | 1.21 |
| Earnings Per Share | -4.06 | -5.31 | -4.81 | -4.76 | -4.36 | -3.19 | -3.65 | - | 0.06 | -16.79 |
| Operating Cash Flow | -238 | -326 | -225 | -196 | -207 | -101 | -63.62 | -49.23 | -11.32 | -29.65 |
| Capital Expenditures | -1.54 | -2.56 | -1.24 | -1.86 | -4.75 | -1.63 | -0.93 | -0.36 | -1.48 | -2.39 |
| Free Cash Flow | -239 | -329 | -226 | -198 | -212 | -102 | -64.55 | -49.59 | -12.80 | -32.04 |
| Cash & Equivalents | 433 | 318 | 463 | 319 | 445 | 309 | 269 | 131 | 188 | - |
| Total Debt | 352 | 215 | 105 | 49.82 | - | - | - | - | - | - |
| Net Cash / Debt | 80.73 | 103 | 359 | 269 | 445 | 309 | 269 | 131 | 188 | - |
| Assets | 578 | 386 | 572 | 343 | 503 | 416 | 326 | 146 | 193 | - |
| Liabilities | 449 | 296 | 222 | 151 | 72.60 | 68.69 | 29.40 | 20.29 | 82.23 | - |
| Book Value | 130 | 88.40 | 347 | 191 | 427 | 348 | 296 | -192 | -206 | - |
Company Profile
Company Details
| Full Name | Portola Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 408 |
| CEO | J. Scott Garland |
Stock Information
| Ticker Symbol | PTLA |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: PTLA |
| IPO Date | May 22, 2013 |
Description
Portola Pharmaceuticals, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.